Join Pharmerit at ISPOR US 2019
MAY 18–22, 2019 • BOOTH #801 • NEW ORLEANS

### SHORT COURSES

<table>
<thead>
<tr>
<th>TITLE</th>
<th>PRESENTER</th>
<th>DATE</th>
<th>TIME</th>
</tr>
</thead>
<tbody>
<tr>
<td>Modeling: Design and Structure of a Model</td>
<td>Shelby Corman</td>
<td>5/18</td>
<td>1:00 PM – 5:00 PM</td>
</tr>
<tr>
<td>Advanced Decision Modeling for Health Economic Evaluations</td>
<td>Elisabeth Fenwick</td>
<td>5/19</td>
<td>1:00 PM – 5:00 PM</td>
</tr>
</tbody>
</table>

### WORKSHOPS AND FORUMS

<table>
<thead>
<tr>
<th>TITLE</th>
<th>PRESENTER(S)</th>
<th>DATE</th>
<th>TIME</th>
<th>LOCATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>An Updated Two-Year Survival Analysis of Axicabtagene Ciloleucel (Axi-Cel) in Relapsed or Refractory Large B-Cell Lymphoma (R/R-LBCL)</td>
<td>Ibrahim Diakite, Sven Klijn, Elisabeth Fenwick, Marc Botteman, Ben van Hout</td>
<td>5/20</td>
<td>4:30 PM – 4:45 PM</td>
<td>MS2</td>
</tr>
<tr>
<td>A Comparison of the Partitioned Survival and Multi-state Extrapolation Methods – A Case Study Based on the Gastric Cancer Trial ATTRACTION-2</td>
<td>Sven Klijn, Sonja Kroep</td>
<td>5/20</td>
<td>4:30 PM – 4:45 PM</td>
<td>MS4</td>
</tr>
<tr>
<td>Alemtuzumab Versus Generic Glatiramer Acetate 20 Mg in Patients with Relapsing Forms of Multiple Sclerosis – A Cost-Effectiveness Study in the United States</td>
<td>Viktor Chirikov, Namita Joshi, Dipen Patel</td>
<td>5/21</td>
<td>4:30 PM – 4:45 PM</td>
<td>CO4</td>
</tr>
<tr>
<td>Getting the Most Out of Value Based Contracting for Medical Devices</td>
<td>Jyoti Aggarwal</td>
<td>5/22</td>
<td>2:00 PM – 3:00 PM</td>
<td>W23</td>
</tr>
</tbody>
</table>

### HEOR THEATER

<table>
<thead>
<tr>
<th>TITLE</th>
<th>PRESENTER</th>
<th>DATE</th>
<th>TIME</th>
<th>LOCATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Making the Patient Voice Count: Demonstrating When, Why, and How to Engage Patients</td>
<td>Caitlyn Solem, Kelly McCarrier</td>
<td>5/21</td>
<td>4:00 PM</td>
<td>HEOR Theater in the Exhibit Hall</td>
</tr>
<tr>
<td>Title</td>
<td>Author</td>
<td>Date</td>
<td>Time</td>
<td>Location</td>
</tr>
<tr>
<td>----------------------------------------------------------------------</td>
<td>---------------------------------------------</td>
<td>------</td>
<td>---------------------</td>
<td>----------</td>
</tr>
<tr>
<td>Cost-Effectiveness of a 24-Month Fixed Duration of Venetoclax in Combination With Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia in the United States</td>
<td>Nicholas Durno</td>
<td>5/20</td>
<td>10:30 AM – 2:00 PM</td>
<td>PCN122</td>
</tr>
<tr>
<td>Economic Burden Associated with Adverse Events Among Patients With Non-Metastatic Prostate Cancer Treated With Bicalutamide, Enzalutamide or Abiraterone Following Androgen Deprivation Therapy (Surgical/Medical Castration)</td>
<td>Anuj Shah, Ruchit Shah, Marc Botteman</td>
<td>5/20</td>
<td>10:30 AM – 2:00 PM</td>
<td>PCN137</td>
</tr>
<tr>
<td>Characteristics and Treatment Patterns for Non-Metastatic Castration Resistant Prostate Cancer (nmCRPC) Patients in Germany, France, and United Kingdom (UK)</td>
<td>Ruchit Shah, Marc Botteman</td>
<td>5/20</td>
<td>10:30 AM – 2:00 PM</td>
<td>PCN156</td>
</tr>
<tr>
<td>Direct Costs and Healthcare Resource Use Among Patients Newly Diagnosed With Advanced Urothelial Carcinoma</td>
<td>Courtney Johnson, Linlin Luo</td>
<td>5/20</td>
<td>10:30 AM – 2:00 PM</td>
<td>PCN172</td>
</tr>
<tr>
<td>Unbiased Treatment Efficacy Detection Methods When Using Patient-Reported Outcomes in Survival-Dependent Drop-Out</td>
<td>Charlie Iaconangelo, Daniel Serrano</td>
<td>5/20</td>
<td>10:30 AM – 2:00 PM</td>
<td>PCN244</td>
</tr>
<tr>
<td>Quality Adjusted Time Without Symptoms of Disease Progression or Toxicity (Q-TWIST) of Nivolumab Plus Ipilimumab (NIVO+IPI) vs Sunitinib (SUN) Among Untreated Advanced Renal Cell Carcinoma (aRCC) Patients with Intermediate or Poor Prognostic Risk</td>
<td>Ruchit Shah, Marc Botteman, Youngmin Kwon</td>
<td>5/20</td>
<td>10:30 AM – 2:00 PM</td>
<td>PCN264</td>
</tr>
<tr>
<td>Cost-Effectiveness of Inhaled Nitric Oxide for Treatment of Infants With Hypoxic Respiratory Failure – Administration at Hospital of Birth vs. Helicopter Transfer to Another Hospital</td>
<td>Shelby Corman</td>
<td>5/20</td>
<td>3:30 PM – 7:00 PM</td>
<td>PIH28</td>
</tr>
<tr>
<td>Economic Burden Associated With Non-Communicable Diseases Among Adults With Depression and Anxiety in the United States</td>
<td>Anuj Shah, Ruchit Shah, Jennifer Stephens</td>
<td>5/20</td>
<td>3:30 PM – 7:00 PM</td>
<td>PMH16</td>
</tr>
<tr>
<td>Patient and Caregiver Preferences for Characteristics of Treatment In Hemophilia A – Literature Review and Qualitative Research</td>
<td>Marc Botteman, Namita Joshi, Xinyi Ng, Erica Horodniceanu, Rachel Shah</td>
<td>5/21</td>
<td>3:30 PM – 7:00 PM</td>
<td>PRO69</td>
</tr>
<tr>
<td>A Cost-Utility Analysis of Two Trabecular Micro-Bypass Stents in Patients With Mild-to-Moderate Open-Angle Glaucoma in France</td>
<td>Kaspar Nieland</td>
<td>5/22</td>
<td>9:30 AM – 2:00 PM</td>
<td>PMD18</td>
</tr>
<tr>
<td>Systematic Review and Benchmarking of US Budget Impact Analyses</td>
<td>Rongzhe Liu, Marc Botteman</td>
<td>5/22</td>
<td>9:30 AM – 2:00 PM</td>
<td>PNS54</td>
</tr>
<tr>
<td>A Newly Developed Power Procedure for Sample Size Planning in COA Validation Studies</td>
<td>Daniel Serrano, Charlie Iaconangelo</td>
<td>5/22</td>
<td>9:30 AM – 2:00 PM</td>
<td>PNS233</td>
</tr>
</tbody>
</table>

Visit us at Booth #801 to meet with our presenters and discuss how we can help you build an integrated HEOR strategy for your products.

Modeling & Meta-Analysis • Patient-Centered Outcomes • Real-World Evidence • Strategic Market Access

www.pharmerit.com

© Copyright 2019 Pharmerit International, LP. All Rights Reserved.